AR004521A1 - Disposicion de liberacion de droga para la liberacion transbucal de peptidos insulinotropicos tipo glucagón a la mucosa bucal de un individuo - Google Patents

Disposicion de liberacion de droga para la liberacion transbucal de peptidos insulinotropicos tipo glucagón a la mucosa bucal de un individuo

Info

Publication number
AR004521A1
AR004521A1 ARP960104865A ARP960104865A AR004521A1 AR 004521 A1 AR004521 A1 AR 004521A1 AR P960104865 A ARP960104865 A AR P960104865A AR P960104865 A ARP960104865 A AR P960104865A AR 004521 A1 AR004521 A1 AR 004521A1
Authority
AR
Argentina
Prior art keywords
glucagon
drug
release
individual
transbucal
Prior art date
Application number
ARP960104865A
Other languages
English (en)
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of AR004521A1 publication Critical patent/AR004521A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una disposición de liberación de droga para la liberación transbucal de un péptido insulinotrópico tipo glucagón a la mucosa bucal de un individuo. Ladisposición de liberación de droga comprende una composición de droga que contiene unacantida d efectiva de un péptido insulinotrópico tipo glucagón yuna cantidad efectiva de un mejorador de la permeabilidad para mejorar la permeabilidad de un péptido insulinotrópico tipo glucagón a través de la mucosabucal y medios paramantener la com posición de la droga en una relación de transferencia de droga con la mucosa bucal. Esta disposición puede presentaruna forma libre, tal como cremas, geles y ungüentos y puede comprender un dispositivo de forma físicadeterminada, tales c omo tabletas, emplastos ypastillas. Un péptido insulinotrópico tipo glucagón preferido es el GLP-1 (7-36) amida.
ARP960104865A 1995-10-23 1996-10-23 Disposicion de liberacion de droga para la liberacion transbucal de peptidos insulinotropicos tipo glucagón a la mucosa bucal de un individuo AR004521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/553,807 US5766620A (en) 1995-10-23 1995-10-23 Buccal delivery of glucagon-like insulinotropic peptides

Publications (1)

Publication Number Publication Date
AR004521A1 true AR004521A1 (es) 1998-12-16

Family

ID=24210844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960104865A AR004521A1 (es) 1995-10-23 1996-10-23 Disposicion de liberacion de droga para la liberacion transbucal de peptidos insulinotropicos tipo glucagón a la mucosa bucal de un individuo

Country Status (12)

Country Link
US (2) US5766620A (es)
EP (1) EP0859606A4 (es)
JP (1) JPH11513982A (es)
KR (1) KR19990064288A (es)
CN (1) CN1202820A (es)
AR (1) AR004521A1 (es)
AU (1) AU716038B2 (es)
BR (1) BR9611139A (es)
CA (1) CA2235369A1 (es)
TW (1) TW416854B (es)
WO (1) WO1997015296A1 (es)
ZA (1) ZA968909B (es)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IT1289608B1 (it) * 1997-02-05 1998-10-15 Angelini Ricerche Spa Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
AU3961599A (en) * 1998-04-30 1999-11-23 Horticulture And Food Research Institute Of New Zealand Limited, The Biological pest control methods and compositions
EP1808160A3 (en) 1998-10-05 2008-03-05 The Penn State Research Foundation Compositions and methods for enhancing receptor-mediated cellular internalization
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
ES2261190T3 (es) † 1999-02-08 2006-11-16 Alza Corporation Vehiculos viscosos no acuosos estables de fase unica y formulaciones que utilizan dichos vehiculos.
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6565879B1 (en) 1999-12-16 2003-05-20 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
WO2001051089A1 (de) * 2000-01-13 2001-07-19 Merck Patent Gmbh Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP2295456A1 (en) * 2000-04-12 2011-03-16 Human Genome Sciences, Inc. Albumin fusion proteins
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
AU2002230509A1 (en) * 2000-11-28 2002-06-11 Martin G. Baum Devices and methods for treating low blood sugar levels
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7090869B2 (en) 2000-12-01 2006-08-15 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
WO2002087622A1 (fr) * 2001-04-24 2002-11-07 Lintec Corporation Preparations orales et supports pour preparations orales
JP4993652B2 (ja) * 2004-03-31 2012-08-08 リンテック株式会社 経口投与剤
US8268333B2 (en) * 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
JP4489356B2 (ja) * 2001-05-11 2010-06-23 メリオン リサーチ スリー リミテッド 浸透促進剤
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
US6642003B2 (en) 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7666337B2 (en) * 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US7425292B2 (en) * 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20100021526A1 (en) * 2001-10-12 2010-01-28 Monosol Rx, Llc Ph modulated films for delivery of actives
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US7910641B2 (en) * 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US20070154527A1 (en) * 2001-10-12 2007-07-05 Monosoirx, Llc Topical film compositions for delivery of actives
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
US7923025B2 (en) 2002-01-16 2011-04-12 Astellas Pharma Inc. Pharmaceutical composition for oral use with improved absorption
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
US8017150B2 (en) * 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20030194420A1 (en) * 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
AU2003268015A1 (en) * 2002-07-22 2004-02-09 Kosmos Pharma Packaging and dispensing of rapid dissolve dosage form
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
DE10240894A1 (de) * 2002-09-04 2004-03-11 Procom Biotechnologische Produktions Gmbh Verstärkung der Resorption von Subtanzen über die Haut und Schleimhaut
US20040122110A1 (en) * 2002-09-06 2004-06-24 Maccabee Mendy S. Effect of vitamin A gel on paranasal sinus mucosal regeneration
BR0315523A (pt) * 2002-10-22 2005-08-30 Waratah Pharmaceuticals Inc Tratamento de diabetes
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8088734B2 (en) * 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
WO2004103390A2 (en) * 2003-05-15 2004-12-02 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
US20040241223A1 (en) * 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP1711532A4 (en) * 2004-01-30 2009-09-16 Waratah Pharmaceuticals Inc USE OF A GLP-1 AGONIST WITH GASTRINIC COMPOUNDS
US7906137B2 (en) * 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
NO345613B1 (no) 2004-07-19 2021-05-10 Biocon Ltd Insulinoligomerkonjugater, formuleringer og bruk derav
EP1786784B1 (en) 2004-08-20 2010-10-27 MannKind Corporation Catalysis of diketopiperazine synthesis
MX2007002189A (es) 2004-08-23 2008-01-11 Mannkind Corp Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos.
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006110551A2 (en) * 2005-04-08 2006-10-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
DE102005033943A1 (de) * 2005-07-20 2007-02-22 Hexal Ag Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für ein Neuroleptikum
CN102614131A (zh) 2005-09-14 2012-08-01 曼金德公司 以提高结晶微粒表面对活性试剂的亲和力为基础的药物配制方法
US20070172515A1 (en) * 2006-01-20 2007-07-26 Monosolrx, Llc Film bandage for mucosal administration of actives
CN101370477A (zh) * 2006-01-20 2009-02-18 莫诺索尔克斯有限公司 薄膜连接的包装及其制备方法
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
AU2007230730B2 (en) 2006-03-24 2013-03-28 Auxilium International Holdings, Inc. Stabilized compositions containing alkaline labile drugs
US8465759B2 (en) * 2006-03-24 2013-06-18 Auxilium Us Holdings, Llc Process for the preparation of a hot-melt extruded laminate
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
CN105232482A (zh) * 2006-04-07 2016-01-13 默里昂研究Iii有限公司 包含增强剂的固体口服剂型
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送系统和活塞组件
AU2007297697A1 (en) * 2006-09-20 2008-03-27 Monosol Rx Llc Edible water-soluble film containing a foam reducing flavoring agent
CN101534799A (zh) * 2006-09-29 2009-09-16 莫诺索尔克斯有限公司 膜埋入式包装及其制备方法
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2008137054A2 (en) 2007-05-01 2008-11-13 Cephalon, Inc. Composition for transmucosal delivery of polypeptides
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
CA2702892C (en) 2007-10-16 2017-02-28 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
HUE025485T2 (en) * 2007-10-24 2016-02-29 Mannkind Corp Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
AU2009244797B2 (en) * 2008-05-07 2015-01-22 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101629154B1 (ko) 2008-06-13 2016-06-21 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
WO2010010555A2 (en) * 2008-07-21 2010-01-28 Transpharma Medical Ltd. Transdermal system for extended delivery of incretins and incretin mimetic peptides
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US20100040727A1 (en) * 2008-08-18 2010-02-18 Monosol Rx, Llc Method for Improving Uniformity of Content in Edible Film Manufacturing
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8282954B2 (en) * 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2400851A4 (en) * 2009-02-25 2012-09-05 Merrion Res Iii Ltd COMPOSITION AND ACTIVE COMPOSITION OF BISPHOSPHONATES
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
WO2010105094A1 (en) 2009-03-11 2010-09-16 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
JP5859433B2 (ja) 2009-06-12 2016-02-10 マンカインド コーポレイション 規定された比表面積を有するジケトピペラジン微粒子
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CN102686741B (zh) 2009-09-28 2018-01-19 精达制药公司 基本稳态药物递送的快速建立和/或终止
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
RS53124B (en) * 2009-11-12 2014-06-30 Acacia Pharma Limited USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY
US9445992B2 (en) 2009-11-25 2016-09-20 Arisgen Sa Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion
CA2783877A1 (en) * 2009-12-10 2011-06-16 A. Mark Schobel Ph sensitive compounds in taste masking within oral thin film strips
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
JP5819949B2 (ja) 2010-06-10 2015-11-24 ミダテック リミテッド ナノ粒子フィルム送達システム
JP6385673B2 (ja) 2010-06-21 2018-09-05 マンカインド コーポレイション 乾燥粉末薬物送達システム
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8925726B2 (en) 2011-04-01 2015-01-06 Mannkind Corporation Blister package for pharmaceutical cartridges
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
GB201200062D0 (en) * 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
EP2861220A2 (en) * 2012-06-14 2015-04-22 Entrega, Inc. Mucoadhesive devices for delivery of active agents
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
CN108578372B (zh) 2013-03-15 2021-07-06 曼金德公司 微晶二酮哌嗪组合物以及方法
CN105407926A (zh) * 2013-05-31 2016-03-16 久光制药株式会社 口腔贴剂
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
WO2015132660A1 (en) * 2014-03-04 2015-09-11 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for transmucosal delivery and methods for treating diabetes in a subject in need thereof
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
BR112018071908A2 (pt) * 2016-04-26 2019-02-05 Lts Lohmann Therapie Systeme Ag forma de administração tipo filme para a liberação transmucosa de peptídeos antidiabéticos e método para produção da mesma
BR112018072539A2 (pt) 2016-05-05 2019-03-26 Aquestive Therapeutics, Inc. composições de epinefrina de administração aumentada
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN106177874A (zh) * 2016-08-30 2016-12-07 郑州市久久不忘生物技术有限公司 一种治疗咳喘的药物贴片及其制备方法
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
DK1288223T3 (da) * 1993-08-09 2005-03-29 Sod Conseils Rech Applic Terapeutiske peptidderivater

Also Published As

Publication number Publication date
TW416854B (en) 2001-01-01
AU716038B2 (en) 2000-02-17
CA2235369A1 (en) 1997-05-01
WO1997015296A1 (en) 1997-05-01
BR9611139A (pt) 1999-04-06
US5766620A (en) 1998-06-16
EP0859606A1 (en) 1998-08-26
AU7464796A (en) 1997-05-15
JPH11513982A (ja) 1999-11-30
US5863555A (en) 1999-01-26
ZA968909B (en) 1997-05-28
CN1202820A (zh) 1998-12-23
EP0859606A4 (en) 2000-03-15
KR19990064288A (ko) 1999-07-26

Similar Documents

Publication Publication Date Title
AR004521A1 (es) Disposicion de liberacion de droga para la liberacion transbucal de peptidos insulinotropicos tipo glucagón a la mucosa bucal de un individuo
AR034132A1 (es) Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica
AR073099A2 (es) Analogos de ghrelina
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
CO5611096A2 (es) Forma de dosificacion farmaceutica para administracion mucosal
PT1196184E (pt) Composicoes para tratamento de disfuncao sexual
ATE227737T1 (de) Gebrauch einer pharmazeutischen zusammensetzung, enthaltend ein appetitzügelndes peptid
ATE493998T1 (de) Pharmazeutische zusammensetzung mit einem exendin-4-peptid
PE20081557A1 (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
MX9706992A (es) Mejoras en composiciones organicas o relacionadas con estas.
IL112112A (en) Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
DK0954314T3 (da) Doseringsformer til bedring af mandlig erektionsdefekt
AR011114A1 (es) COMPOSICIoN FARMACÉUTICA LIBRE DE LACTOSA EN FORMA GRANULADA O EN MEZCLA PARA EL TRATAMIENTO DE DESoRDENES INDUCIDOS POR HISTAMINA.
ES2190653T3 (es) Productos de reaccion del acido hialuronico y de aminoacidos naturales y su utilizacion en composiciones cosmeticas y farmaceuticas.
ES2173420T3 (es) Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion.
ES2101164T5 (es) Composiciones farmaceuticas orales para el suministro especifico al colon.
TW200603781A (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
PE20221595A1 (es) Uso terapeutico de un conjugado de accion prolongada de un triple agonista que tiene actividad en todos los receptores de glucagon/glp-1/gip para enfermedades pulmonares
HUP0000137A2 (hu) Szabályozott hatóanyag-felszabadulású analgetikumot tartalmazó gyógyszerkészítmény
IL142284A0 (en) A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
YU36401A (sh) Farmaceutska kompozicija za stimulator osetljivosti na insulin sa modifikovanim ispuštanjem
ES2052114T3 (es) Composicion farmaceutica altamente absorbible.
BR9915123A (pt) Composição de uma substância farmaceuticamente ativa e dispensador
PE20011121A1 (es) Composicion farmaceutica que comprende un compuesto ciclico con un grupo sulfamato

Legal Events

Date Code Title Description
FA Abandonment or withdrawal